Evidence map›Paper›PMID 37426178›Full record

ArticleFrontiers in nutrition2023

NASAFYTOL

Jean Gérain, Melanie Uebelhoer, Bérénice Costes, Julie Herman, Sandra Pietri, Anne-Françoise Donneau, Justine Monseur, Yves Henrotin

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in nutrition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06974058 (Evaluation of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06974058 nacompletednot on this mapstarted 2025, after this paper: background citation

Evaluation of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms: A Pragmatic, Interventional Clinical Study.

TypeinterventionalSponsorLiaquat University of Medical & Health SciencesRan2025 to 2025Enrolled15ConditionsLong COVIDArmsNasafytol® (Quercetin/Curcumin Supplement)
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jean GérainDepartment of Internal Medicine, CHIREC Hospital Group, Brussels, Belgium.
Melanie UebelhoerArtialis SA, Avenue Hippocrate 5, Liège, Belgium.
Bérénice CostesArtialis SA, Avenue Hippocrate 5, Liège, Belgium.
Julie HermanArtialis SA, Avenue Hippocrate 5, Liège, Belgium.
Sandra PietriArtialis SA, Avenue Hippocrate 5, Liège, Belgium.
Anne-Françoise DonneauBiostatitics Unit, Département des Sciences de la Santé Publique, Université de Liège, Liège, Belgium.
Justine MonseurBiostatitics Unit, Département des Sciences de la Santé Publique, Université de Liège, Liège, Belgium.
Yves HenrotinArtialis SA, Avenue Hippocrate 5, Liège, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The effect and safety of Nasafytol Methods: This exploratory, open-label, randomized, controlled trial was carried out among hospitalized adults with COVID-19 infection. Participants were randomly assigned to receive Nasafytol Results: Twenty-five patients received Nasafytol Conclusion: Supplementation with Nasafytol

Indexed as

clinical trialcoronavirusCOVID-19curcuminefood supplementquercetineSARS–CoV-2vitamin D

Identifiers

PMID37426178
PMCPMC10324407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.